Denken Sie bei HIV-Infizierten auch ans Herz!

Kardiovaskuläre Erkrankungen

Think also of the heart of HIV-infected people

Durch die antiretrovirale Therapie hat sich die Lebenserwartung von Menschen mit einer HIV-Infektion erheblich verbessert. Bei der Betreuung HIV-positiver Patienten muss daher auch die frühzeitige Behandlung kardiovaskulärer Risikofaktoren berücksichtigt werden.

This is a preview of subscription content, log in to check access.

Abb. 1
Abb. 2

Literatur

  1. 1.

    Robert Koch Institut. Epidemiologisches Bulletin 14.November 2019 / Nr. 46 Schätzung der Zahl der Neuinfektionen und der Gesamtzahl von Menschen, die in Deutschland mit HIV leben:483-92

  2. 2.

    Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte AD, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014;384(9939):241–248.

    Article  Google Scholar 

  3. 3.

    https://daignet.de/site-content/hiv-leitlinien/leitlinien-1

  4. 4.

    Gueler A, Moser A, Calmy A, Günthard HF, Bernasconi E, Furrer H, Fux CA, Battegay M, Cavassini M, Vernazza P, Zwahlen M, Egger M; Swiss HIV Cohort Study, Swiss National Cohort. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. AIDS. 2017 Jan 28;31(3):427–436

    Article  Google Scholar 

  5. 5.

    Esser S, Arendt M, Schulze C, Holzendorf V, Brockmeyer NH, Jöckel K-H, Erbel R, Reinsch N on behalf of HIV HEART Study Group and Heinz Nixdorf Recall Investigative Group. More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population difer by sex. 9th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Paris, France, 23-25 July, 2017 (MOPDB0101).

  6. 6.

    Nou E, Lo J, Hadigan C, Grinspoon SK. Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol. 2016 Jul;4(7):598–610

    CAS  Article  Google Scholar 

  7. 7.

    Althof KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, Rimland D, Rodriguez-Barradas MC, Dubrow R, Park LS, Skanderson M, Shiels MS, Gange SJ, Gebo KA, Justice AC; Veterans Aging Cohort Study (VACS). Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defning cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015 Feb 15;60(4):627–38

    Article  Google Scholar 

  8. 8.

    Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ Jr, Skarbinski J, Chmiel JS, Hart R, Wei SC, Loustalot F, Brooks JT, Buchacz K. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. Clin Infect Dis. 2016 Dec 1;63(11):1508–1516

    Article  Google Scholar 

  9. 9.

    Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, D’Agostino RB Sr. Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. Circulation. 2018 May 22;137(21):2203–2214

    Article  Google Scholar 

  10. 10.

    Neumann T, Esser S, Potthof A, Pankuweit S, Neumann A, Breuckmann F, Neuhaus K, Kondratieva J, Buck T, Müller-Tasch T, Wachter R, Prettin C, Gelbrich G, Herzog W, Pieske B, Rauchhaus M, Löfer M, Maisch B, Mügge A, Wasem J, Gerken G, Brockmeyer NH, Erbel R; HIV-HEART Study Investigative Group.. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res. 2007;12:243–248.

    PubMed  Google Scholar 

  11. 11.

    Schmermund A, Möhlenkamp, S., Stang, A., Grönemeyer, D., Seibel, R., Hirche, H., Mann, K., Sifert, W., Lauterbach, K., Siegrist, J., Jöckel, K. H. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middleaged subjects: rationale and design of the Heinz Nixdorf RECALL Study. American heart journal. 2002 Aug 2:212–8.

    Google Scholar 

  12. 12.

    Esser S, Gelbrich G, Brockmeyer N, Goehler A, Schadendorf D, Erbel R, Neumann T, Reinsch N. Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study. Clin Res Cardiol. 2013 Mar;102(3):203–13

    Article  Google Scholar 

  13. 13.

    Esser S, Brockmeyer NH, Hower M, Holzendorf V, Schulze C, Arendt M, Neumann T, Reinsch N, on behalf of HIV HEART Study Group. Association between cardiovascular events and HIVspecifc risk factors. 24th Conference on Retroviruses and Opportunistic Infections (CROI 2017) 13.–16. February 2017 Seattle, Washington, USA (P633).

  14. 14.

    Esser S, Arendt M, Schulze C, Holzendorf V, Brockmeyer NH, Jöckel KH, Erbel R, Reinsch N on behalf of HIV HEART Study Group and Heinz Nixdorf Recall Investigative Group. HIV+ Men Matched By Age And FRS With Controls Have More Cardiovascular Events. 25th Conference on Retroviruses and Opportunistic infections CROI 2018, 4.-7.3.2018 Boston, Massachusetts, USA (P691).

  15. 15.

    Reinsch N, Schulze C, Holzendorf V, Dolf S, Streeck H, Brockmeyer NH, Potthof A, Hower M, Kwirant F, Jöckel K-H, Schmidt B, Esser S on behalf of HIV HEART Study Group. Impact of HIV specifc and traditional risk factors on the incidence of cardiovascular events in HIV-positive males over time. 10th IAS Conference on HIV Science, 21-24 July 2019 Mexico City, Mexico, TUPEB203

  16. 16.

    Nou E, Lo J, Grinspoon SK. Infammation, immune activation, and cardiovascular disease in HIV. AIDS. 2016 Jun 19;30(10):1495–509

    CAS  Article  Google Scholar 

  17. 17.

    D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735

    Article  Google Scholar 

  18. 18.

    Ryom L, Lundgren JD, El-Sadr WM, Reiss P, Phillips A, Kirk O, Weber R, Sabin C, Mocrof A. Association between Cardiovascular Disease & contemporarily used Protease Inhibitors, CROI 2017, Seattle USA #128LB

  19. 19.

    Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008 Sep 12;22(14):F17–24.

    Article  Google Scholar 

  20. 20.

    http://www.eacsociety.org/fles/guidelines_10.0-english.pdf

  21. 21.

    Reinsch N, Streeck H, Holzendorf V, Schulze C, Neumann T, Brockmeyer NH, Kehrmann J, Schadendorf D, Esser S; HIV HEART Study Group. B-type natriuretic peptides for the prediction of cardiovascular events and mortality in patients living with HIV: Results from the HIV-HEART study. Int J Cardiol. 2019 Apr 15;281:127–132.

    Article  Google Scholar 

  22. 22.

    Reinsch N, Neuhaus K, Esser S, Potthof A, Hower M, Mostardt S, Neumann A, Brockmeyer NH, Gelbrich G, Erbel R, Neumann T; German Competence Network Heart Failure; German Competence Network for HIV/AIDS. Are HIV patients undertreated? Cardiovascular risk factors in HIV: results of the HIV-HEART study. Eur J Prev Cardiol. 2012 Apr;19(2):267–74.

    Article  Google Scholar 

  23. 23.

    https://www.hiv-druginteractions.org/

  24. 24.

    Reinsch N, Arendt M, Geisel MH, Schulze C, Holzendorf V, Warnke A, Neumann T, Brockmeyer NH, Schadendorf D, Eisele L, Erbel R, Moebus S, Jöckel KH, Esser S; HIV HEART Study Group and the Heinz Nixdorf Recall Investigative Group. Prolongation of the QTc interval in HIV-infected individuals compared to the general population. Infection. 2017 Oct;45(5):659–667. 2017 Aug 3. doi: https://doi.org/10.1007/s15010-017-1053-9

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to PD Dr. med. Stefan Esser.

Additional information

This article is part of a supplement not sponsored by the industry.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Esser, S. Denken Sie bei HIV-Infizierten auch ans Herz!. MMW - Fortschritte der Medizin 162, 20–23 (2020). https://doi.org/10.1007/s15006-020-0641-2

Download citation

Keywords

  • HIV-infection
  • cardiovascular risk factors
  • cardiovascular events
  • antiretroviral therapy